Polaryx Therapeutics PLYX
NASDAQ PLYX
$1.95 +0.08 (+4.28%)
At close: Nov 11, 2026 · 4:00 PM EST

Polaryx Therapeutics (PLYX) Cash from Financing Activities (2025)

Updated

Polaryx Therapeutics' Cash from Financing Activities was $4.47 million in FY2025, down 37.9% from $7.19 million in FY2024.

Analysis

Polaryx Therapeutics (PLYX) Cash from Financing Activities (2025) Analysis & Trends

  • Per Business Quant data, Cash from Financing Activities in earlier years was $7.19 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -7.22 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -8.53 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 6.82 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -2.43 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 6.63 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -4.39 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -1.53 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -2.51 Bn
10 Polaryx Therapeutics 93.21 Mn 68.83 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 250,000.00
API Access

Polaryx Therapeutics Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=PLYX&period=max&api_key=YOUR_API_KEY